Physicians' Academy for Cardiovascular Education

New therapeutic options can make a difference for diabetic patients with high CV risk

Aug. 29, 2017 - Prof. John E Deanfield, MD - London, UK

Novel insights in the management and prognosis of pulmonary hypertension

Aug. 29, 2017 - ESC 2017, Barcelona, Spain - Prof Nazzareno Galiè - Bologna, Italy

Neurotoxin injection did not prevent the common complication of AF after cardiac surgery

Nov. 15, 2017 - AHA 2017 - Anaheim, CA, USA - Nathan Waldron, MD - Durham, NC, USA.

New ACC/AHA hypertension guidelines empasize risk assessment

Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Prof. Clyde Yancy - Chicago, IL, USA

A coordinated effort to organise STEMI care improved treatment time and patient outcomes

Nov. 14, 2017 - AHA 2017 - Anaheim, CA - James Jollis, MD - Chapel Hill, NC, USA

Positive lesson from a negative trial comparing peri-operative continuation or interruption of DOAC therapy

Nov. 15, 2017 - AHA 2017 - Anaheim, CA - David H. Birnie, MD - Ottawa, ON, Canada

Machine learning program predicts that drinking more coffee lowers risk of CVD and stroke

Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Laura M Stevens - Aurora, CO, USA

Highly adhering to a plant-based diet is associated with a lower risk of developing HF

Nov. 14, 2017 - AHA 2017 - Anaheim, CA - AHA 2017 - Anaheim, CA, USA

Sodium Bicarbonate and N-Acetylcysteine tested for the prevention of serious adverse outcomes

Nov. 14, 2017 - AHA 2017 - Anaheim, CA - AHA 2017 - Anaheim, CA, USA

Good BP measurement depends more on appropriate technique than on absence of staff

Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Karen Johnson - Memphis, TN, USA

Target for BP lowering differs between Europe and USA

Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Prof. Clyde Yancy - Chicago, IL, USA

Restrictive transfusion is non-inferior to liberal approach during cardiac surgery

Nov. 14, 2017 - AHA 2017 - Anaheim, CA - David Mazer - Toronto, Ont, Canada

Analogous to LDL-c, the lower the better also seems true for inflammation

Nov. 14, 2017 - Paul Ridker, Boston, MA, USA

Clinical outcomes and adverse effects comparable across various BP measurement methods in SPRINT

Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Dr. Sripal Bangalore - NYU Langone, New York, NY, USA.

New ACC/AHA Hypertension Guidelines: stress on accuracy BP measurement method and lifestyle changes ánd a new target

Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Paul Whelton, MD (Tulane University, New Orleans, LA, USA

More insight into effects of treatment with PCSK9 inhibition from 5 new FOURIER analyses

Nov. 14, 2017 - Anaheim, CA, USA - Robert Giugliano - Boston, MA, USA

Robust benefits for CV and limb event risk in PAD patients on PCSK9 inhibition

Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Bonaca - Boston, MA, USA

Greater relative and absolute risk reduction in high-risk subgroup with previous MI treated with PCSK9 inhibition

Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Sabatine - Boston, MA, VS

PCSK9 inhibition & CV events: Review of recent and upcoming hard endpoint outcome trials

Aug. 26, 2017 - Barcelona, Spain - Peter Sever, MD London, United Kingdom - PACE-CME symposium at ESC 2017

Ultime notizie sulla terapia: Un farmaco anti-infiammatorio riduce eventi cardiovascolari maggiori

Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Are the COMPASS trial results applicable on a broader population in the REACH registry?

Dec. 14, 2017 - Darmon A, et al. - Eur Heart J 2017

COMPASS-eligible patients represented a substantial fraction of the spectrum of stable CAD and PAD outpatients from the REACH registry.

Midlife systemic inflammation may promote the development of white matter dysfunction

Dec. 13, 2017 - Walker KA, et al. - Stroke 2017

In a sub-analysis of the ARIC study, midlife systemic inflammation was associated with the development of chronic microangiopathic structural white matter abnormalities in the elderly.

Release of ADA 2018 Standards with new recommendations for diabetes patients with CVD

Dec. 12, 2017 - news

Notably, new recommendations in the 2018 edition of the ADA Standards of Care reflect advances in diabetes treatment with antidiabetic drugs with CV benefit.

GLP-1 receptor agonist approved by FDA for treatment of T2DM

Dec. 12, 2017 - news

Based on the results of the SUSTAIN trial, semaglutide is approved by the FDA for the treatment of T2DM patients.

First time randomized trial shows remission of T2DM with dietary and lifestyle intervention

Dec. 11, 2017 - Lean MEJ et al., - The Lancet, 2017

The DIRECT trial evaluated a weight management program delivered by primary care. On average, weight reduced by 10 kg and almost half achieved and maintained remission of T2DM at 12 months after starting the intervention.

New onset and paroxysmal AF increase the risk of adverse outcomes in HF

Dec. 6, 2017 - Mogensen UM et al. - J Am Coll Cardiol. 2017

In heart failure patients with a reduced EF, paroxysmal AF and new onset AF were associated with a greater risk of adverse outcomes, including HF hospitalization and stroke, but not mortality.

Genetically determined dyslipidemia associated with abdominal aortic aneurysm

Dec. 6, 2017 - Harrison SC, et al. - JAMA Cardiol 2017

Genetically determined elevation of LDL-c and TG levels was associated with an increased risk of abdominal aortic aneurysm, whereas elevated HDL-c level was associated with a lower risk thereof.

CETP is associated with atherosclerosis only in specific subpopulations

Dec. 5, 2017 - Christen T et al. - J Clin Lipidol. 2017

Mendelian randomisation suggests that CETP is not causally related to atherosclerosis in the general population, but only in men with normal glucose, HDL, and TG levels, and in women with ¬¬high CV risk or abnormal fasting glucose.

FDA Approval for evolocumab as secondary prevention in CVD patients

Dec. 4, 2017 - news

Following FDA Priority Review, evolocumab is the only PCSK9 inhibitor approved to reduce risk of myocardial infarction, stroke and coronary revascularization in adults with established CVD.

First FDA clearance for medical device accessory for smartwatch

Dec. 4, 2017 - news

KardiaBand evaluates heart rate and physical activity, and instantly pushes notifications to take an EKG, which can be recorded in 30 second with its integrated sensor.

The risk of vascular dementia, but not Alzheimer’s disease, is higher in post-MI patients

Dec. 4, 2017 - Sundbøll J, et al. - Circulation 2017

Patients with a history of MI have a higher risk of vascular dementia, particularly if they additionally have a history of stroke, probably due to common risk factors for both diseases.

HFrEF patients with low SBP do tolerate target dose of ARNI

Nov. 30, 2017 - Senni M, et al. - Eur J Heart Fail 2017

In an analysis of the TITRATION study, the majority of patients with low screening SBP tolerated the initiation/up-titration to target dose level of sacubitril/valsartan using a gradual up-titration regimen.